PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
1.18
OCF/share of $1–2 – Below ideal. Philip Fisher might question if expansions or cost improvements are needed.
1.17
FCF/share $1–2 – Subpar. Peter Lynch would look for operational improvements or cost cuts to expand free cash.
0.97%
Capex under 20% of OCF – Very capital-light. Warren Buffett would relish the strong free cash flows.
-3.59
Negative ratio implies negative OCF or net income. Benjamin Graham would investigate which signals deeper distress.
62040.00%
OCF-to-sales above 40% – Exceptional cash conversion. Benjamin Graham would verify if margins or payment terms drive this.